Medicago

company

About

Medicago is a biotechnology company focused on the research, development, production, and commercialization of vaccines in Canada.

  • 501 - 1000

Details

Last Funding Type
Post-IPO Equity
Last Funding Money Raised
$25M
Industries
Biotechnology,Commercial,Health Care,Medical
Founded date
Jan 1, 1997
Number Of Employee
501 - 1000
Operating Status
Active

Medicago Inc., a biotechnology company, focuses on the research, development, production, and commercialization of vaccines in Canada. The company develops its vaccines based on its proprietary technologies, including the plant-based Proficia technology and Virus-Like Particles (VLP) technology. Its product candidate includes H5N1 pandemic influenza VLP vaccine, which has completed a Phase I human clinical trial. The company is also developing H1N1 VLP vaccine for Influenza A/California/04/09 virus; and seasonal influenza vaccines. Medicago Inc. has collaboration agreements with Viridis S.A.; Genopole biopark to manufacture pandemic and seasonal influenza vaccines; and Philip Morris International to produce a therapeutic protein with a humancompatible glycosylation pattern. The company was incorporated in 1997 and is headquartered in Quebec City, Canada.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
1
$25M
Medicago has raised a total of $25M in funding over 2 rounds. Their latest funding was raised on Sep 27, 2011 from a Post-IPO Equity round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Sep 27, 2011 Post-IPO Equity $25M 1 Detail

Investors

Number of Lead Investors
Number of Investors
1
Medicago is funded by 1 investors. AgeChem Venture Fund are the most recent investors.
Investor Name Lead Investor Funding Round
AgeChem Venture Fund Post-IPO Equity